E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumerigenesis

312Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.
Get full text

Abstract

In breast cancer, inactivating point mutations in the E-cadherin gene are frequently found in invasive lobular carcinoma (ILC) but never in invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) adjacent to ILC has previously been shown to lack E-cadherin expression, but whether LCIS without adjacent invasive carcinoma also lacks E-cadherin expression and whether the gene mutations present in ILC are already present in LCIS is not known. We report here that E-cadherin expression is absent in six cases of LCIS and present in 150 cases of ductal carcinoma in situ (DCIS), both without an adjacent invasive component. Furthermore, using mutation analysis, we could demonstrate the presence of the same truncating mutations and loss of heterozygosity (LOH) of the wild-type E-cadherin in the LCIS component and in the adjacent ILC. Our results indicate that E-cadherin is a very early target gene in lobular breast carcinogenesis and plays a tumour-suppressive role, additional to the previously suggested invasion-suppressive role.

Cite

CITATION STYLE

APA

Vos, C. B. J., Cleton-Jansen, A. M., Berx, G., De Leeuw, W. J. F., Ter Haar, N. T., Van Roy, F., … Van De Vijver, M. J. (1997). E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumerigenesis. British Journal of Cancer, 76(9), 1131–1133. https://doi.org/10.1038/bjc.1997.523

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free